This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Lost in translation: the valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles
Translational Medicine Communications Open Access 18 November 2019
-
Innovative payer engagement strategies: will the convergence lead to better value creation in personalized medicine?
EPMA Journal Open Access 13 February 2017
-
The translational potential of human induced pluripotent stem cells for clinical neurology
Cell Biology and Toxicology Open Access 03 December 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Dimasi, J. A. & Grabowski, H. G. “The cost of biopharmaceutical R&D: is biotech different?” Managerial Decision Econom. 28, 469–479 (2007).
Pisano, G. P. Science Business: The Promise, The Reality, and the Future of Biotech 1–256 (Harvard Business School, 2006).
Morgan, P. et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov. Today 17, 419–424 (2012).
Morieux, Y. Smart rules: six ways to get people to solve problems without you. Harv. Bus. Rev. 89, 78–84, 86, 136 (2011).
Acknowledgements
The authors gratefully acknowledge the contributions of P. Swiatek, N. Srikanth, M. Herant, R. Howard and especially Y. Morieux to this work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors of this article are employees of The Boston Consulting Group (BCG), a management consultancy that works with the world's leading biopharmaceutical companies on R&D productivity issues. The research for this specific article was funded by BCG's Health Care practice.
Supplementary information
Supplementary information S1 (box)
Dataset and analysis methods (PDF 352 kb)
Rights and permissions
About this article
Cite this article
Ringel, M., Tollman, P., Hersch, G. et al. Does size matter in R&D productivity? If not, what does?. Nat Rev Drug Discov 12, 901–902 (2013). https://doi.org/10.1038/nrd4164
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4164
This article is cited by
-
Inflammation across tissues: can shared cell biology help design smarter trials?
Nature Reviews Rheumatology (2023)
-
Lost in translation: the valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles
Translational Medicine Communications (2019)
-
Expanding the medicinal chemistry synthetic toolbox
Nature Reviews Drug Discovery (2018)
-
Impact of a five-dimensional framework on R&D productivity at AstraZeneca
Nature Reviews Drug Discovery (2018)
-
Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications
Nature Reviews Drug Discovery (2018)